<?xml version="1.0" encoding="UTF-8"?>
<abstract abstract-type="author-highlights" id="abs0015">
 <title>Highlights</title>
 <p>
  <list list-type="simple" id="ulist0010">
   <list-item id="u0010">
    <label>•</label>
    <p id="p0010">For 5 decades, DMCs have monitored RCTs for safety and benefit.</p>
   </list-item>
   <list-item id="u0015">
    <label>•</label>
    <p id="p0015">In 2020, the World Health Organization declared covid-19 disease to be a pandemic.</p>
   </list-item>
   <list-item id="u0020">
    <label>•</label>
    <p id="p0020">Numerous trials have emerged to evaluate potential therapeutics and vaccines.</p>
   </list-item>
   <list-item id="u0025">
    <label>•</label>
    <p id="p0025">Covid-19 trials bring new challenges to the DMC process, due to the epidemic speed.</p>
   </list-item>
   <list-item id="u0030">
    <label>•</label>
    <p id="p0125">Patients are being recruited and outcome data accumulating very rapidly.</p>
   </list-item>
   <list-item id="u0035">
    <label>•</label>
    <p id="p0130">DMCs oversight very important for extreme emergencies such as coronavirus epidemics.</p>
   </list-item>
  </list>
 </p>
</abstract>
